Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease : vimarsana.com

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical TrialDSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 -- Ocugen, Inc. ,...

Related Keywords

United States , Peter Chang , Head Of Communications , Twitter , Ocugen Inc , Nuclear Hormone Receptor , Linkedin , Exchange Commission , Established Low Dose , Tolerable Dose , Medium Dose Cohort , Data Safety , Monitoring Board , Huma Qamar , Chief Medical Officer , Orphan Receptor , Private Securities Litigation Reform Act ,